Acura Pharmaceuticals, Inc. (ACUR)
- Previous Close
0.0100 - Open
0.0110 - Bid --
- Ask --
- Day's Range
0.0100 - 0.0100 - 52 Week Range
0.0001 - 0.0500 - Volume
40 - Avg. Volume
1,052 - Market Cap (intraday)
660,018 - Beta (5Y Monthly) 49.26
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.
www.acurapharm.com9
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: ACUR
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACUR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACUR
Valuation Measures
Market Cap
660.02k
Enterprise Value
795.02k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.36
Price/Book (mrq)
3.71
Enterprise Value/Revenue
0.51
Enterprise Value/EBITDA
-1.35
Financial Highlights
Profitability and Income Statement
Profit Margin
-56.24%
Return on Assets (ttm)
-58.46%
Return on Equity (ttm)
--
Revenue (ttm)
1.56M
Net Income Avi to Common (ttm)
-879k
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
84.27%
Levered Free Cash Flow (ttm)
-1.1M
Research Analysis: ACUR
Company Insights: ACUR
ACUR does not have Company Insights